Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis

Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling L (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 45

Article Number: 108649

DOI: 10.1016/j.dib.2022.108649

Abstract

Over the past decade, cancer immunotherapy with immune checkpoint inhibitors (ICIs) has significantly improved the outcome of many malignancies. However, with the broad use of ICIs, neurological immune related adverse events (irAE) are increasingly recognized. ICI-induced encephalitis (ICI-iE) is a particularly severe irAE, often leading to treatment termination, long-term sequalae or death. Despite its high morbidity and mortality, data on clinical features and diagnostic criteria are limited. We aimed to define clinical, radiologic and laboratory characteristics of ICI-iE and identify factors that discriminate it from anti-leucine-rich glioma-inactivated (anti-LGI)-1 encephalitis and herpes simplex virus (HSV)-1 encephalitis – two alternative causes of encephalitis – to increase the awareness of ICI-iE and improve its diagnosis and management. To that end, we retrospectively collected 30 cases of ICI-iE that were reported to the Side Effect Registry Immuno-Oncology (SERIO) and 46 cases of anti-LGI1 encephalitis or herpes simplex virus (HSV)-1 encephalitis that presented to a large German neurological referral center (Charité Universitätsmedizin Berlin) between January 2015 and September 2021. Signs and symptoms, imaging and electroencephalogram features, laboratory findings and outcome measures were assessed using standardized case report forms as well as patients’ medical records and compared between the groups. The data reported here represents the largest primary cohort of patients with ICI-iE to date and the first comparison with other types of encephalitis. As all three disorders – ICI-iE, HSV-1 encephalitis and anti-LGI1 encephalitis – are rare neurological entities, this dataset can be used as a reference in future clinical studies on ICI-induced neurotoxicity, neurological autoimmune disorders, and central nervous system infections.

Authors with CRIS profile

Involved external institutions

Ludwig-Maximilians-Universität (LMU) Germany (DE) Peter MacCallum Cancer Centre Australia (AU) Charité - Universitätsmedizin Berlin Germany (DE) Netherlands Cancer Institute (NKI) Netherlands (NL) Universitätsklinikum Würzburg Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Side Effect Registry Immuno-Oncology (SERIO) Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Universitätsklinikum Essen Germany (DE) National Cancer Center Hospital East / 国立がん研究センター東病院 Japan (JP) University Hospital Geelong Australia (AU) Sozialstiftung Bamberg Germany (DE) Kantonsspital St.Gallen Switzerland (CH) University of Sydney (USYD) Australia (AU) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Klinikum der Universität München Germany (DE)

How to cite

APA:

Müller-Jensen, L., Zierold, S., Versluis, J.M., Boehmerle, W., Huehnchen, P., Endres, M.,... Heinzerling, L. (2022). Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data in Brief, 45. https://dx.doi.org/10.1016/j.dib.2022.108649

MLA:

Müller-Jensen, Leonie, et al. "Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis." Data in Brief 45 (2022).

BibTeX: Download